LABORIZON has been 100% owned by BIOGROUP since July 2020.

At what enterprise value was LABORIZON acquired in 2020?

During the acquisition of LABORIZON by BIOGROUP in 2020, the transaction's Enterprise Value is estimated to be in the range of €300–700M.

What was the EV/EBITDA of LABORIZON when it was acquired by BIOGROUP?

The estimated EV/EBITDA multiple for LABORIZON is in the range of 10x - 18x.

What was the EV/Revenue multiple of LABORIZON when it was acquired by BIOGROUP?

The estimated EV/Revenue multiple for LABORIZON is in the range of 2x - 6x.

When was LABORIZON acquired by BIOGROUP?

LABORIZON was acquired by BIOGROUP in 2020.

What was the revenue of LABORIZON at the time of the deal?

The revenue of LABORIZON at the time of the deal is estimated to be in the range of €100–200M.

What was the EBITDA of LABORIZON during the acquisition?

LABORIZON's EBITDA is estimated to be in the range of €25–50M.

How is the data for the LABORIZON acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LABORIZON deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/nos-exclus/analyses-medicales-laborizon-devrait-sunir-a-biogroup-1186395

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaLABORIZON

07/2020

LABORIZON acquired by BIOGROUP

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV €300–700M

Context

Biogroup acquired Laborizon. This strategic move allowed Biogroup to expand its footprint in Western France (Brittany, Normandy, Centre Val de Loire) and strengthen its position as a French leader alongside Cerba. The deal was finalized despite the COVID-19 pandemic, which underscored the critical nature of medical analysis infrastructure.

LABORIZON, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A major regional medical biology group formed by the merger of five laboratory groups. It operates approx. 100 local sites and 6 technical platforms, serving the Center, Normandy, and Brittany regions.

Ent. Value

€300–700M

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2020	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes
09/2020	VAM INVESTMENTS	DEMENEGO	ITALY	Ophthalmology
07/2020	ORPEA	BRINDLEY HEALTHCARE	IRELAND	Nursing Homes
06/2020	ASKLEPIOS KLINIKEN	RHÖN-KLINIKUM	GERMANY	Clinics / Hospitals
03/2020	ORPEA	TLC GROUP	IRELAND	Nursing Homes
02/2020	VIVALTO VIE	SOLIMAR	SPAIN	Nursing Homes
02/2020	AMUNDI PRIVATE EQUITY / SOCIETE GENERALE CAPITAL PARTENAIRES	VIVALTO VIE	FRANCE	Nursing Homes
02/2020	CLARIANE	INICEA	FRANCE	Clinics / Hospitals
01/2020	ARDIAN	SANTE CIE	FRANCE	Health Providers
01/2020	VIVALTO SANTÉ	MATHILDE MÉDICAL DÉVELOPPEMENT	FRANCE	Clinics / Hospitals

REFERENCES

Valuation range: EV €300–700M

Revenue range: €100–200M

EBITDA range: €25–50M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LABORIZON by BIOGROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: biogroup